Thermo Fisher Scientific Revenue Recognized from Contract Liability decreased by 5.1% to $1.29B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.1%, from $1.36B to $1.29B. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher values indicate successful delivery of services or products for which cash was previously received.
Revenue recognized during the current period that was previously recorded as a contract liability (deferred revenue) at...
Commonly disclosed in revenue recognition notes for companies with subscription or long-term contract models.
tmusz_contract_liability_revenue_recognized| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $370.00M | $170.00M | $1.28B | $710.00M | $340.00M | $1.30B | $680.00M | $350.00M | $1.32B | $670.00M | $360.00M | $1.36B | $1.29B |
| QoQ Change | — | -54.1% | +652.9% | -44.5% | -52.1% | +282.4% | -47.7% | -48.5% | +277.1% | -49.2% | -46.3% | +277.8% | -5.1% |
| YoY Change | — | — | — | +91.9% | +100.0% | +1.6% | -4.2% | +2.9% | +1.5% | -1.5% | +2.9% | +3.0% | -5.1% |